Industrial scale production of ultrapure DNA strands

Important results from the project

Current poorly performing DNA synthesis methods are limiting the development and implementation of life-changing technologies and therapies. Our company’s mission is to enable gene technologies and therapies at global scale, by producing long and ultrapure DNA molecules with our enzymatic technology. To achieve that, we aimed to design a regulatory plan and to implement a legal strategy.

Expected long term effects

Thanks to Vinnova’s support Moligo Technologies successfully designed an actionable regulatory strategy which, once implemented, will enable the use of our DNA molecules both for medical devices and therapeutics. In addition, our legal strategy is already facilitating the acquisition of top-notch collaborators and clients. These results will exponentially expand our market segments, helping our company to become a biomanufacturing leader for pharmaceutical and biotech top corporates.

Approach and implementation

Design and implementation of our regulatory and legal strategies have been successfully achieved through the cooperation of our scientific team together with company’s advisors and consultants. The design of our regulatory strategy has been laid out identifying interventions for (i) Process control and quality assurance and (ii) certification needed depending on the downstream applications of our DNA molecules. Our legal plan has been implemented considering long-term implications of early-stage co-development and co-financing programs with our potential partners.

External links

Our mission is to enable the next generation of DNA based tools producing long and pure, single stranded DNA.